Balchem Corporation develops, manufactures, and markets specialty ingredients and performance products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. The company is headquartered in New Hampton, New York.
109 articles
Balchem Corporation's SVP and Chief R&D Officer Ren Anthony Gonzalez disclosed share holdings, revealing that most direct shares are restricted stock vesting over one to three years.
Argus Research raised its price target for Balchem Corporation to $185.00 from $167.84, noting the company's development of specialty performance ingredients for various industries.
A Discounted Cash Flow analysis indicates Balchem Corporation is undervalued by roughly 25%, supported by $177.6 million in trailing twelve-month free cash flow. Capacity expansion offers upside, thou
Balchem announced research from the University of Arkansas showing Optifolin+ significantly enhances cellular DNA methylation and SAM levels. These findings support the ingredient's role in epigenetic
Balchem Corporation announced that key executives, including CEO Ted Harris, will attend the 9th Annual Wells Fargo Consumer Conference on September 23, 2026. The company specializes in developing and
Balchem Corp reported 18.70 billion MXN in annual revenue, with its Human Nutrition and Health segment contributing the majority at 11.89 billion MXN. The United States was the top regional market, ge
Balchem Corporation outlines strategies for manufacturers to meet rising protein demand in meat snacks, noting opportunities from GLP-1 trends and the use of MeatShure® microencapsulated acids.
Balchem Corporation reported strong Q2 2026 financial results, sparking debate over whether its stock is fully valued. With a P/E ratio of 34.3x exceeding the US Chemicals industry average, investors
Balchem Corporation reported strong Q2 2026 results with higher sales and net income, completing a $55.49 million share repurchase. Management confidence is evident, though risks regarding product inn
Balchem Corp, a chemicals company, reported Q2 2026 earnings with an 11.2% sales growth across all three segments. The update includes current stock performance and analyst ratings for investors.
Balchem released Q2 2026 results and a buyback update, with analysts estimating the stock is 16% undervalued driven by a new microencapsulation facility. High P/E ratios suggest potential valuation ri
H.C. Wainwright raised Balchem's price target to $215 following Q2 2026 results that exceeded revenue and earnings estimates, citing consistent growth and 16 consecutive years of dividend increases.
Balchem Corporation reported record quarterly revenue and adjusted EBITDA, yet its stock gained only 3% despite strong profitability trends. Analysts note the high 34.1x P/E ratio requires further eva
Balchem Corporation reported $1.04 billion USD in annual revenue, led by its Human Nutrition and Health segment. The United States contributed the majority of sales, totaling $759.45 million.
Balchem Corp reported record consolidated sales of $284 million and adjusted EBITDA of $78 million for Q2 2026, driven by growth in Animal and Human Nutrition segments despite higher input costs.
Balchem Corporation reported Q2 2026 revenue of $284.0 million, an 11% increase driven by its Human Nutrition and Health segment. Adjusted earnings of $1.49 per share beat estimates, though the stock
Balchem Corporation reported strong Q2 2026 financial results, exceeding consensus estimates with $1.49 adjusted earnings per share and $284 million in revenue. Growth was driven by robust demand for
Balchem Corporation reported record Q2 fiscal 2026 financial results, with net sales increasing 11.2% year-over-year to $284.0 million. The company posted GAAP net earnings of $44.6 million and genera
Balchem Corporation reported record Q2 2026 net sales of $284.0 million, an 11.2% increase year-over-year. The company amended its credit agreement and repurchased $29 million in stock reflecting conf
Balchem Corporation reported second-quarter adjusted earnings per share of $1.49, exceeding analyst expectations of $1.40. The results indicate strong profitability for the specialty ingredients manuf
Various ETFs, including those from BlackRock and Vanguard, hold Balchem Corporation stock, primarily focusing on small-cap and extended market segments. The data includes financial metrics such as ass
Balchem Corp (BCPC) ranks 6th among 65 Chemicals companies with a financial score of 9.04, posting $270.71 million in quarterly revenue and an 8.72% year-over-year profit increase.
Balchem Corp shares traded near $162 with a slight decline, though analysts maintain a Buy rating with a target price of $200.75. The company is valued fairly within the Chemicals industry, supported
Balchem Corp ranks 28th in the Chemicals industry with a 7.00 institutional confidence score; institutional shareholding fell 4.74% QoQ to 88.34%, while top shareholder ETHSX increased its stake to 2.
Balchem Corp reported 822.23M CHF annual revenue, driven by its Human Nutrition and Health segment (522.74M CHF). The U.S. was the top geographic market, contributing 602.07M CHF.
Balchem Corporation published a detailed cash flow statement covering quarterly and annual periods, including operating, investing, and financing metrics. The report features an FAQ section explaining
Analysts project Balchem Corp (BCPC) to rank 33rd in the Chemicals industry with a $191.00 price target. Next-quarter revenue is expected at $268.50M with an EPS of $1.40.
Balchem Corporation is scheduled to report Q2 2026 earnings on July 31, with analysts projecting EPS of $1.43 and revenue of $268.5 million. Market attention focuses on input cost and demand trends fo
Balchem Corporation amended its credit facility with JPMorgan, increasing revolving commitments to $650 million and extending maturity to 2031. The changes aim to improve liquidity and lower borrowing
The global Vitamin K2 market is projected to grow from $175 million in 2024 to $339.9 million by 2031 at a 13.5% CAGR. Growth is driven by health supplement demand, particularly in the aging Asia Paci
ChemBrief